Drug General Information |
Drug ID |
D09TQP
|
Former ID |
DNC006802
|
Drug Name |
3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H12N2
|
Canonical SMILES |
C1C2=CC=CC=C2C3=C1C(=NN3)C4=CC=CC=C4
|
InChI |
1S/C16H12N2/c1-2-6-11(7-3-1)15-14-10-12-8-4-5-9-13(12)16(14)18-17-15/h1-9H,10H2,(H,17,18)
|
InChIKey |
NZNCUNCNFCUBOK-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Proteoglycans in cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
VEGF and VEGFR signaling network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY network
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferation
|
WikiPathways
|
Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
Signaling by VEGF
|
Angiogenesis
|
References |
REF 1 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4371-5. Epub 2006 Jun 5.Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. |